Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
NCT07129642Phase 1Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Graves' disease, sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Remission of Graves disease at 12 months and Incidence of Adverse Events at 6 months. Started Aug 2025; status: recruiting.
02
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT07129642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129642.